Wockhardt

Wockhardt Ltd.

Type	Public company (: WOCKPHARMA)
Industry	Pharmaceuticals Health care
Founded	1960s
Founder	Habil Khorakiwala
Headquarters	Mumbai, India
Area served	Worldwide
Key people	Habil Khorakiwala (Chairman) Murtaza Khorakiwala (managing director) Huzaifa Khorakiwala (Executive Director)
Products	Formulations Biopharmaceuticals Nutrition products Vaccines
Revenue	₹46.14 billion (US$690 million)
Total equity	$1.4 billion
Number of employees	7,900 (2013)
Website	www.wockhardt.com

Wockhardt Ltd. is a pharmaceutical and biotechnology company headquartered in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. It is a global company with more than half of its revenue coming from Europe. In 2011–2012 its UK and USA sales alone were US$475 million. It has market presence in emerging markets such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. The Company has a market capitalisation of over ₹211 billion (US$3.1 billion) and an annual turnover of ₹36 billion (US$530 million). It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company employs over 8,600 people globally.Wockhardt Hospitals is a subsidiary of the Wockhardt Group.

Wockhardt was founded by Habil Khorakiwala in the 1960s. His father Fakhruddin T. Khorakiwala had acquired Worli Chemical Works in 1959. This was incorporated as Wockhardt Pvt. Ltd., in 1973. Wockhardt Ltd. was incorporated on July 8.1999. Wockhardt is often confused as a multinational because of its German-sounding name.

Wockhardt is the first company outside of the US and Europe to manufacture recombinant human insulin.

Wockhardt's acquisitions include Wallis Laboratory, UK (1998), Merind, India (1998), CP Pharmaceuticals, UK (2003), Espharma GmbH, Germany (2004), Dumex India (2006), Pinewood Laboratory, Ireland (2006) and Negma, France (2007). Wockhardt's debt following the acquisitions was close to Rs 38 billion, and Habil Khorakiwala quit as managing director. The board of directors, on 31 March 2009 approved the appointments of Habil Khorakiwala's sons Murtaza Khorakiwala and Hozaifa Khorakiwala as managing director and Executive Director respectively.